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Abstract Hepatic lipase (HL) plays a role in the metabo-
lism of pro- and anti-atherogenic lipoproteins affecting
their plasma level and composition. However, there is con-
troversy regarding whether HL accelerates or retards ath-
erosclerosis. Its effects on different lipoprotein classes
show that, potentially, HL may promote as well as decrease
atherogenesis. Studies in animals with genetically modu-
lated HL expression show that it depends on the model
used whether HL acts pro- or anti-atherogenic. In humans,
HL activity seems to correlate inversely with atherosclerosis
in (familial) hypercholesterolemia, and positively in hyper-
triglyceridemia. In normolipidemia, HL activity is weakly as-
sociated with coronary artery disease (CAD). Genetically
low or absent HL activity is usually associated with in-
creased CAD risk, especially if plasma lipid transport is im-
paired due to other factors. Since HL promotes the uptake
of lipoproteins and lipoprotein-associated lipids, HL may
affect intracellular lipid content.  We hypothesize that the
prime role of HL is to maintain, in concert with other fac-
tors (e.g., lipoprotein receptors), intracellular lipid homeo-
stasis. This, and the uncertainties about its impact on hu-
man atherosclerosis, makes it difficult to predict whether
HL is a suitable target for intervention to lower CAD risk.
First, the physiological meaning of changes in HL activity
under different conditions should be clarified.
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Many factors contribute to the development and pro-
gression of atherosclerosis. There are good reasons to be-
lieve that hepatic lipase (HL) is one of these factors. HL
plays a role in the metabolism of several pro- and anti-
atherogenic lipoproteins. In humans, a change in HL ac-
tivity is often associated with changes in the plasma level
and composition of different lipoproteins, and with an in-
creased or lowered risk of coronary artery disease (CAD).
However, despite of extensive research during the last de-
cade and the use of genetically modified animal models,
the questions of whether HL is a pro- or anti-atherogenic
 
enzyme, and whether we can or should modulate HL to
decrease CAD risk, have not been unambiguously an-
swered. In vitro and in vivo studies suggest the pro- as well
as anti-atherogenic potential of HL (
 
Table 1
 
). In recent
studies, HL was identified as focal point in the develop-
ment of CAD. However, the investigators came to opposite
conclusions with regard to the influence of HL on athero-
genesis. While Zambon and coworkers (1) concluded “re-
gression of coronary atherosclerosis results from . . . a new
pathway of HL-mediated (read decreased HL) improve-
ment in LDL buoyancy,” Dugi and coworkers (2) stated
“Low hepatic lipase activity is a novel risk factor for coro-
nary artery disease.”
In this review, we will summarize evidence that connects
HL to CAD. We will discuss the potential impact of HL on
CAD based on its proposed roles in (lipoprotein) metabo-
lism. Finally, we will try to answer the question of whether
or not modulation of HL expression/activity is an option to
reduce atherosclerotic risk. To limit the number of litera-
ture references, we will as much as possible refer to recent
reviews in which more detailed information can be found.
HEPATIC LIPASE
The nature and molecular characteristics of HL are re-
viewed in an accompanying review in this issue (3). There-
fore, we summarize only major characteristics here.
The gene encoding the HL glycoprotein is a member of
the lipase gene family. This gene, indicated as 
 
LIPC
 
, is ex-
pressed, although to very different levels, in (almost) all
species. Once glycosylated, HL has a molecular mass
around 60 kDa. The protein is primarily synthesized in
the liver and bound extracellularly to parenchymal cell
surfaces in the space of Disse. In mice, guinea pigs, and
golden hamsters, part of its activity circulates in the
 
Abbreviations: apo, apolipoprotein; CAD, coronary artery disease;
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plasma. In humans, its activity can be measured in the
blood plasma after intravenous heparin injection to re-
lease the enzyme from the hepatic extracellular matrix. In
addition to liver, HL is found in the adrenal glands and
ovaries. The liver-associated HL activity represents more
than 95% of the total activity and is therefore the most im-
portant activity for plasma lipoprotein metabolism. Re-
cently, HL expression was detected in macrophages. Al-
though macrophage-derived HL may be important for the
atherosclerotic process, we will not discuss it, because little
is known about this activity at the moment.
HL affects the phospholipid, triglyceride, and choles-
terol content of several lipoprotein classes by its phospho-
lipase A-1 and triglyceridase activities. Additionally, HL
may influence lipoprotein metabolism by bridging lipo-
proteins to lipoprotein receptors or other cell surface com-
ponents. As depicted in 
 
Fig. 1
 
, HL is involved in the metab-
olism of HDL, apolipoprotein (apo)B-100, and apoB-48
containing lipoproteins [recently reviewed in (4–6)].
ASSOCIATION WITH ATHEROSCLEROSIS
 
Human studies
 
As shown in Table 1, HL may be linked to atherosclero-
sis in many ways. In humans, we have to rely on its activity
in post-heparin plasma or the presence of functional ge-
netic variants to assess the relation of HL with CAD.
In conditions with increased atherosclerotic risk, HL ac-
tivity is often high. Males exhibit higher HL activity than
premenopausal women, HL is lowered upon physical ac-
tivity (7), and increased by smoking (8). In addition, HL
activity increases with the degree of insulin-resistance in
type 2 diabetes (9) and with omental fat mass in women
(10). In familial combined hyperlipidemia (FCH) (11)
and type 2 diabetes, HL may contribute to the develop-
ment of the atherogenic lipid profile, characterized by low
HDL cholesterol (HDL-C) levels and the presence of
small-dense LDL (9). Increased HL activity is also re-
ported in familial hypercholesterolemia (FH), a condition
with greatly enhanced atherogenic risk (12). In homozy-
gote FH patients, however, HL activity is strongly inversely
associated with the extent of coronary calcification (13).
Low HL activity has been reported in patients with clin-
ically overt CAD (2, 14, 15). In a population of 200 men
undergoing elective coronary angiography, the extent of
CAD correlated inversely with HL activity (
 
r
 
 
 

 
 
 

 
0.19, 
 
P
 
 
 

 
0.001), indicating that approximately 4% of the variance
in CAD could be explained by HL. However, 45% of these
men were on lipid-lowering drugs. This may have influ-
enced the association as lipid-lowering drugs are reported
to reduce HL activity (16, 17). In 720 normolipidemic
 
TABLE 1. Arguments for pro- and anti-atherogenic potential of hepatic lipase
Impact on Human Lipoprotein Metabolism
Pro-atherogenic Decreases LDL size
Anti-atherogenic Stimulates HDL cholesterol (ester) uptake (reverse cholesterol transport)
Stimulates post-prandial lipid clearing
Stimulates IDL clearing
Stimulates pre
 
 
 
HDL, HDL3 formation
Animal Studies
Pro-atherogenic Deficiency attenuates atherosclerosis in apoE k.o. mice
Overexpression augments plaque size in rabbits
Anti-atherogenic Over-expression in mice decreases aortic cholesterol deposition
Inhibition of activity in apoA-II overexpressing mice increases aortic cholesterol deposition 
Animals low in HL show diet-induced hyperlipidemia
Associations with Human Lipoprotein Profile
Pro-atherogenic Activity inversely correlated with HDL (2)
Activity inversely correlated with LDL size
Anti-atherogenic Activity inversely correlated with post-prandial lipids
Activity inversely correlated with LpCIII:B
Association with Human Atherosclerosis Promoting Diseases and Other Conditions
Pro-atherogenic Activity high in males compared to females
Activity positively associated with insulin-resistance and high in type 2 diabetes 
Activity positively correlated with omental fat mass, fasting insulin
Activity high in FH
Anti-atherogenic Activity low in hypothyroidism
Association with Human CAD
Pro-atherogenic Decrease in activity during hypolipidemic drug treatment associated with increased 
LDL size and decreased CAD
Anti-atherogenic Activity low in CAD patients (if accompanied by low CETP)
Activity inversely associated with calcification in homozygote FH
Activity predictor of CAD regression after dietary intervention
Deficiency associated with increased CAD risk
The table summarizes arguments in favor of a pro- or anti-atherogenic potential of HL based on different ex-
perimental approaches.
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or slightly hyperlipidemic males with angiographically
proven CAD (REGRESS study), HL activity was not differ-
ent from age-matched controls (18).
The relationship between HL activity and changes in
CAD during intervention was studied in the Leiden Inter-
vention Trial. Subjects with severe CAD were subjected to
a strictly vegetarian diet for 2 years. HL activity deter-
mined at the end of the study period correlated positively
with regression of coronary atherosclerotic lesion size (
 
r
 
 
 


 
0.55) (14); it appeared to be the most important predic-
tor of regression. However, during hypolipidemic treat-
ment of hypertriglyceridemic CAD patients with a familial
history of CAD who participated in the FATS study, Zam-
bon and coworkers (19) found that a decrease in HL activ-
ity correlated with a decrease in coronary stenosis (
 
r
 
 
 

 
0.57). It thus appears that in humans, HL activity is not
unambiguously related to the risk, presence, or progres-
sion of CAD.
Correlation between HL activity and CAD does not nec-
essarily reflect a causal relationship. Association of geneti-
cally induced variation of HL expression with CAD is
more likely to be indicative for a contribution of HL to
CAD risk.
HL deficiency is generally associated with increased
CAD risk [reviewed by Connelly and Hegele (20)]; how-
ever, the number of affected individuals is low, so the con-
tribution to CAD is difficult to quantify. For the general
population, a common functional variant in the 
 
LIPC
 
 pro-
moter [
 
HL
 
-C480T (18) or 
 
LIPC
 
-514C
 

 
T (21)] is of inter-
est. This base substitution is linked with three other base
variants in the proximal 
 
LIPC
 
 promoter (21). The collec-
tive presence of the linked variants represents two alleles
that will be indicated as 
 
LIPC
 
 C- and T-allele. The T-allele
leads to a diminished HL promoter activity and is associ-
ated with a 15–30% lower post-heparin HL activity in
humans. Two studies compared the occurrence of the
T-allele in normolipidemic subjects with and without CAD
(18, 22). In both studies, the frequency of the T-allele
tended to be slightly higher among the CAD patients than
in the controls. Recently, Andersen and coworkers re-
ported in the Copenhagen Heart Study a 1.7- (95% CI:
1.2–2.4) fold higher risk of CAD in homozygote T-allele
carriers relative to homozygote C-allele carriers (23). In
healthy, mildly hypercholesterolemic T-allele carriers,
Fan et al. (24) found a reduced adenosine-stimulated
coronary blood flow, an early sign of coronary dysfunc-
tion. In men with suspected CAD, Dugi and coworkers
(2) found that the T-allele was significantly associated
with more severe CAD. Hokanson and coworkers (25)
found the T-allele associated with coronary calcification
in type 1 diabetes. These data show that a genetic variant
leading to a 15–30% lowering of HL activity may increase
Fig. 1. Central role of hepatic lipase (HL) in lipid metabolism. The oval panels represent the major pathways of plasma lipid transport in
which HL is proposed to play a role. Within the panels, processes affected by HL are given. Between the lipoproteins of the different pathways,
lipids are exchanged under the influence of transfer proteins, cholesterol ester transfer protein (CETP), and phospholipid transfer protein
(PLTP) as represented by double headed arrows. HL interacts with the different pathways by hydrolyzing lipids, notably phospholipids and tri-
glycerides, or by bridging the lipoprotein to lipoprotein receptors or heparan sulphates on hepatocytes. In this way, HL connects plasma lipid
transport to intracellular lipid metabolism in the liver.
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atherosclerotic risk, but that it does not constitute a ma-
jor risk factor.
In their review on HL deficiency, Connelly and Hegele
(20) proposed that HL deficiency increases atherogenic
risk, especially in the presence of a second genetic or envi-
ronmental factor affecting lipoprotein levels. Data of
Hirano and coworkers (26) support this idea. They found
that subjects with low HL activity exhibited increased CAD
only in the presence of genetically determined low choles-
teryl ester transfer protein (CETP) activity. We recently
obtained further support for this view by comparing the
presence of CETP and LIPC variants in men with athero-
sclerosis (REGRESS study) with non-symptomatic con-
trols. The CAD patients were 7.16 more often carrier of
the combined 
 
LIPC
 
 T/T (low HL) and 
 
CETP
 
 B2/B2 (low
CETP) genotype than the controls. Moreover, the com-
bined homozygosity for the 
 
LIPC
 
 T-allele and the 
 
CETP
 
 B2
allele associated within the REGRESS group with a larger
progression of CAD compared with other allelic combina-
tions (unpublished). It thus appears that while a slightly
reduced HL expression in itself has little effect on CAD, it
may significantly increase CAD risk in the presence of
other lipid abnormalities. The apparent potentiation of
the impact of HL on CAD by other factors is further illus-
trated by the difference in association of HL with CAD in
two studies by Dugi and coworkers in homozygote FH and
other patients. HL activity and CAD were stronger corre-
lated in the homozygous FH patients than in the other pa-
tients (2, 13). In the FH patients, HL activity and lipopro-
tein lipase (LPL) dimer mass together accounted for 85%
of the variability in coronary calcification (
 
r
 
 
 

 
 0.92, 
 
P
 
 
 

 
0.0005).
If interaction with environmental and other genetic fac-
tors is important, the 
 
LIPC
 
 C
 

 
T variation might affect
lipid metabolism and CAD risk differently in different
populations; and vice versa, the atherogenicity of other
factors may be modulated by differences in the presence
the 
 
LIPC
 
 C
 

 
T genotype as well. In this respect it is of in-
terest that the frequency of the C
 

 
T polymorphism varies
greatly among different ethnic groups. While the T-allele
is the common allele in African Americans with a fre-
quency of 0.53 (27), in Caucasians the T-allele frequency
is approximately 0.20 (18, 21). Subjects of East Asian de-
scent show intermediate values (28). This means that
when allele frequencies in populations are compared with
the established effect of an HL variant on CAD risk, the
ethnic background and other confounding factors should
be taken into account.
 
Animal models
 
Causality between HL overexpression or deficiency and
atherosclerosis has been studied in genetically modified
models. In cholesterol-fed transgenic mice, overexpres-
sion of HL led to a diminished aortic cholesterol content
in spite of reduced HDL levels (29). Inhibition of HL ac-
tivity in mice by overexpression of apoA-II increased HDL
levels but accelerated atherosclerosis (30, 31). In athero-
genic apoE deficient female mice, however, HL deficiency
led to smaller aortic plaque size (32). In cholesterol-fed
rabbits, HL overexpression attenuated the rise in plasma
lipids, but increased lesion thickness (33). These data
clearly support the view that the effect of HL on athero-
genesis is dependent on the context in which it is studied.
Taken together, the human and animal studies show
that HL variably associates with atherosclerosis and CAD
risk. In humans, the strongest, but opposite, correlations
between HL activity and CAD exist in homozygous FH
and hypertriglyceridemia. Genetically decreased HL in
humans carrying the 
 
LIPC
 
 T-allele tends to increase CAD
risk, but only to a limited extent. In conjunction with vari-
ants in other genes (and/or environmental factors), the
effect of the T-allele may be augmented.
HL presumably affects CAD through its effects on lipo-
protein metabolism. In the following sections, we will dis-
cuss the potential consequences of these effects for ath-
erosclerosis.
ASSOCIATION WITH PRO- AND
ANTI-ATHEROGENIC LIPOPROTEINS
 
Role in HDL metabolism and reverse
cholesterol transport
 
HL activity is usually inversely correlated with HDL-C
levels. Therefore, high HL activity is often considered to
increase CAD risk. However, this association may be
caused by several distinct mechanisms. Opposite changes
in HL activity and apoA-I synthesis or lecithin:cholesterol
transferase (LCAT) activity (34) may result in an inverse
correlation between HDL and HL without reflecting a
causal relationship (5). Still, there are good reasons to as-
sume a role of HL in HDL metabolism. In humans, the
HL gene locus is associated with 25% of the variation in
HDL-C levels (35). The 
 
LIPC
 
 T-allele increases HDL-C, al-
though this effect differs greatly among different popula-
tions and is sometimes even absent (36) [for a review see
Cohen (6)]. It is generally agreed that HL is involved in
the interconversion of HDL subclasses by hydrolyzing
phospholipids and triglycerides [reviewed by Navab et al.
(37)]. Since HL is a membrane bound enzyme, this may
lead to uptake of the hydrolysis products into the cell. In
1980, we proposed a role for HL in reverse cholesterol
transport (RCT) based on the assumption that degrada-
tion of HDL phospholipids renders the particle more
prone to deliver cholesterol (ester) to the lipase-contain-
ing tissues (38). It has now been well established by in
vitro and in vivo studies that HL promotes the uptake of
HDL-C (ester) (39, 40), either directly and/or by facilitat-
ing uptake via lipoprotein receptors such as the putative
HDL receptor (HDLR), scavenger receptor class B type I
(SR-BI) (41, 42). By stimulating HDL-C (ester) uptake,
HL may lower HDL-C levels. In all animal studies in which
HL expression was modulated, HDL levels and HL expres-
sion changed in the opposite direction. A decrease in HDL
as occurred in HL overexpressing transgenic mice (29) was
also observed upon hepatic overexpression of SR-BI in
mice liver (43). In both conditions, the low HDL-C level
may be associated with an accelerated RCT.
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Delipidation of HDL by HL leads to the generation of
smaller HDL subclasses (e.g., HDL3 and/or pre
 

 
 HDL).
These subclasses stimulate cholesterol efflux from cells ef-
ficiently [reviewed by Fielding and Fielding (44)]. Choles-
terol efflux from peripheral tissues represents the first
step in RCT. Thus, potentially, HL may stimulate RCT by
promoting HDL-C (ester) uptake in the liver as well as by
affecting HDL functionality. Involvement of HL in RCT is
regarded a major mechanism by which HL may influence
CAD risk [reviews by von Eckerdstein et al. (45, 46) and
Hill and MacQueen (47)].
In addition, changes in HL activity may alter the (anti)
atherogenic properties of HDL in different ways. In apoE
deficient mice, HL deficiency increased the cholesterol ef-
flux inducing capacity of HDL (32). In apoA-II overex-
pressing mice, however, where HL activity is inhibited,
HDL lost its anti-inflammatory capacity and became pro-
inflammatory (31). This, and the fact that HL affects the
metabolism of other lipoproteins as well, explains why in-
creased HDL levels due to lowered HL activity do not al-
ways decrease peripheral lipid deposition. It illustrates
once more that the HDL level is often a poor indicator of
atherogenic risk in animal models. Nofer et al. (48) re-
viewed the role of HDL in atherosclerosis in genetically
modified mouse models. It appeared that only in 19 out of
the 31 strains, HDL was inversely associated with athero-
sclerosis.
In humans, peripheral cholesterol once taken up by
HDL and esterified by LCAT may be transferred to the
liver via two distinct routes (
 
Fig. 2
 
). Both routes are con-
nected via lipid transfer proteins. In the direct route,
which involves HL, the liver takes up HDL-C directly. In
the indirect route, HDL-C ester is first transferred to the
apoB-100 or apoB-48 containing lipoproteins, and is fi-
nally taken up by receptor-mediated endocytosis (e.g.,
LDLR) [for reviews see (46, 47)]. In the absence of CETP,
the direct route represents the major RCT pathway.
As discussed above, in experimental animals that lack
CETP, HL is often inversely associated with atherosclero-
sis. In humans with low CETP, HL activity also seems in-
versely associated with CAD. Hence, the anti-atherogenic
properties of HL seem to prevail when the indirect route
of RCT is (relatively) blocked. This may occur in situa-
tions with low CETP as well as in situations with decreased
LDLR activity, such as FH. If cholesterol ester transfer to
apoB-containing lipoproteins and LDLR activity are high,
the HL-mediated pathway may be of less importance
for RCT.
The presence of CETP has, however, additional conse-
quences for the role of HL in HDL metabolism. Choles-
terol esters are transferred to apoB containing lipopro-
teins in exchange for triglycerides. During cholesterol ester
transfer, HDL is depleted of cholesterol ester and enriched
in triglyceride. This explains the generally observed inverse
Fig. 2. Direct and indirect routes of reverse cholesterol transport in humans. Cholesterol from peripheral tissues is transported to the liver
by two distinct mechanisms [for reviews see (46, 47)]. In the direct route, which involves HL (represented by the red symbol), the liver takes
up HDL cholesterol (HDL-C) via mechanisms in which lipoprotein receptors also, like the scavenger receptor class B type I (SR-BI), may take
part. In the indirect route, HDL-C ester is first transferred to apolipoprotein (apo)B containing lipoproteins in exchange for triglycerides.
The apoB containing lipoproteins are taken up via receptor-mediated endocytosis.
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correlation between plasma triglyceride and HDL-C lev-
els. HDL triglycerides are substrate for HL. Hydrolysis of
the HDL triglycerides and phospholipids by HL results in
delipidation of HDL. Since delipidated HDL is more
prone to degradation than lipid-rich HDL, HDL degrada-
tion increases. To what extent cholesterol esters are ex-
changed for triglycerides depends on the triglyceride con-
centration. In hypertriglyceridemic conditions, such as
type 2 diabetes, more HDL-C will be transferred to the
apoB containing lipoproteins and HDL will become tri-
glyceride-enriched (49). HL-mediated hydrolysis of tri-
glyceride in the cholesterol ester poor HDL will not con-
tribute greatly to HDL-C ester uptake and RCT, but to an
accelerated degradation of apoA-I. This suggests that dur-
ing hypertriglyceridemia, the effect of HL on HDL metab-
olism may be rather pro- than anti-atherogenic.
In conclusion, HL may affect HDL metabolism, levels,
and composition in several ways.
With regard to RCT, the effect of HL on HDL metabo-
lism may differ under different conditions. Possibly, it is
beneficial during hypercholesterolemia, but unfavorable
during hypertriglyceridemia.
 
Role in IDL/LDL metabolism
 
Human as well animal studies have shown that HL also
affects the metabolism of apoB-100 containing lipopro-
teins. Demant and coworkers (50), employing stable iso-
tope techniques, reported in HL deficient humans a
50% diminished conversion of small VLDL to IDL and a
near complete absence of IDL to LDL conversion. This
was consistent with the development of a type III-like li-
poprotein profile described in HL deficient subjects
(20). We found that the T-allele, which lowers HL ex-
pression partially, dose dependently increased LpCIII:B
levels in healthy young participants of the EARS-II study
(51). IDL-like lipoproteins accumulate also in condi-
tions with decreased HL activity, such as hypothyroidism
(52).
IDL is a major determinant of CAD risk (53). There-
fore, low HL activity might lead to increased atherosclero-
sis due to the accumulation of IDL. On the other hand, in
humans, HL may also promote the generation of athero-
genic small-dense LDL. LDL triglycerides may be derived
from triglyceride-rich VLDL in exchange for cholesterol
ester under influence of CETP. Hydrolysis of these LDL
triglycerides by HL results in the generation of small-
dense LDL [reviewed by Havel (54)]. Zambon and co-
workers (19) showed in hypertriglyceridemic males with
CAD that intensive lipid lowering resulted in increased
LDL buoyancy, which was strongly (
 
r
 
 
 

 
 0.79) correlated
with decreased HL activity. The increased LDL size was
the major determinant of regression of atherosclerosis.
The decrease in HL may thus lead to regression of CAD
during treatment of such patients. Therefore, Zambon
and coworkers proposed HL as a focal point in the devel-
opment of atherosclerosis and as a potential site of treat-
ment (1).
However, HL is not always a determinant of LDL size.
Neither in a study on 126 dizygote female twins, nor in a
 
genetic linkage study in 19 families, was the HL gene lo-
cus linked to LDL size (55, 56). In the normolipidemic
REGRESS population, we found that HL associated with
the presence of the LDL subclass pattern B, representing
small-dense LDL. This relationship disappeared in multi-
variate analysis when triglycerides and HDL were taken
into account (57). It may be that only if LDL is greatly en-
riched in triglycerides, as in hypertriglyceridemia, HL ac-
tivity becomes rate-limiting in the hydrolysis of LDL tri-
glycerides and thus in the generation of small-dense LDL.
In non-hypertriglyceridemic conditions, the amount of
VLDL triglycerides exchanged may be limiting and deter-
mine the LDL size.
Taken together, by interfering with the metabolism of
apoB-100 containing lipoproteins, HL may have pro- as
well as anti-atherogenic effects. During hypertriglyceri-
demia (its role in the formation of small-dense LDL) the
pro-atherogenic effect of high HL may prevail over the
potentially beneficial effects on IDL metabolism.
 
Role in postprandial lipid clearing
 
The third major mechanism by which HL may affect
atherosclerosis is postprandial lipid clearing. Chylomi-
cron-remnants are considered to be highly atherogenic.
HL may promote postprandial lipid (chylomicron-rem-
nant) clearing via several mechanisms [reviewed by Yu
and Cooper (58)]. In addition, species with low HL are
prone to develop dietary hyperlipidemia. Rabbits, for ex-
ample, readily develop diet-induced hypercholesterol-
emia, which is attenuated by overexpression of HL (59).
The influence of HL on these processes clearly repre-
sents an anti-atherogenic potential of the protein.
ADDITIONAL MECHANISMS
 
Interaction with carbohydrate metabolism
and insulin-resistance
 
While the role of HL in lipoprotein metabolism is con-
sidered to be the major mechanism by which it may affect
atherosclerosis, novel evidence suggests that HL may in-
terfere with glucose homeostasis as well.
Pihlajamaki and coworkers (60) studied healthy con-
trols and members of families with familial combined hy-
perlipidemia in a Finnish population. They showed that
the 
 
LIPC
 
 T-allele was not only associated with dyslipidemia
but also with insulin-resistance.
In the EARS-II study population, consisting of healthy
young males, we found that interaction of the 
 
LIPC
 
T-allele with the 
 
APOC3
 
-482T variant resulted in a signifi-
cantly increased glucose and insulin response during oral
glucose tolerance testing (61). In this light, it is of interest
that the omental fat mass, a determinant of insulin-sensi-
tivity, is associated with HL activity (10, 62, 63).
Although little is known about the consequences of these
findings, the link between HL expression and glucose ho-
meostasis constitutes an exciting new field of research and
may represent a novel link between HL and CAD.
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IMPORTANCE OF HL IN (PLASMA)
LIPID METABOLISM
 
Importance of HL and interaction with other factors of 
lipid metabolism
 
While HL may affect the metabolism of several lipopro-
teins and CAD risk, its quantitative contribution to these
processes is not clear. HL activity is often only weakly cor-
related to lipoprotein levels and to CAD risk. This does
not disqualify HL as an important player in these pro-
cesses. A number of factors may obscure the relationship
between HL and lipoproteins and atherosclerosis. HL ac-
tivity may be stimulated or inhibited by apoA-I, apoA-II,
apoA-IV, apoC-III, and apoE . In situ, the nature of its lipo-
protein substrate may vary depending on the composition
of lipoproteins as discussed above for HDL and LDL.
CETP may play an important role in this.
Similarly, phospholipid transfer protein (PLTP) facili-
tates the transfer of phospholipids [recently reviewed by
Huuskonen and Ehnholm (64) and van Tol (65)]. If HDL
phospholipids are degraded by HL, HDL phospholipids
may be replenished under the influence of PLTP by, for
example, the phospholipid-rich surface fragments gener-
ated during the lipoprotein lipase-mediated degradation
of triglyceride-rich lipoproteins. The in situ HL phospho-
lipase activity is thus dependent on LPL and PLTP activi-
ties, and on the amount of triglyceride-rich lipoproteins.
Therefore, the impact of HL on lipoprotein metabo-
lism will vary depending on the amount and nature of po-
tential substrates, and on its activity relative to that of the
transfer proteins. Consequently, in post-heparin plasma-
measured HL activity may only remotely reflect its in situ
activity.
 
HL linking intracellular lipid metabolism to plasma
lipid transport
 
HL is usually studied in relation to its role in plasma li-
poprotein transport. Very little is known about the impact
that HL may have on intracellular lipid homeostasis. Its
tissue-bound character and exclusive localization in tis-
sues with an active cholesterol metabolism, however, point
to involvement in intracellular lipid homeostasis. While
different pathways of plasma lipoproteins are connected
by lipid transfer proteins, HL, in concert with lipoprotein
receptors, links the plasma lipid transport to intracellular
lipid metabolism (Fig. 1). In fact, the main function of the
enzyme is probably the maintenance of intracellular lipid
homeostasis. The influence on plasma lipoprotein trans-
port may be secondary to this role. 
 
Figure 3
 
 shows HL as
one of the factors that affects intracellular lipid metabo-
lism. There are good indications that HL is a key player in
intracellular cholesterol homeostasis in different tissues.
Gene-targeted inactivation of HL expression in mice, and
acute inhibition of HL activity in rat adrenals, resulted in
a greatly stimulated adrenal SR-BI expression (66, 67). In
rat liver and ovaries, inactivation of HL activity by antibod-
Fig. 3. HL as a factor in hepatic intracellular lipid homeostasis. Lipids are taken up by the liver via several mechanisms. Lipoprotein recep-
tors mediate in the endocytosis of whole lipoproteins. HL (red symbol) may modulate the binding of lipoproteins (e.g., chylomicron-rem-
nants) to receptors (58), or stimulate the uptake of HDL-C (ester) directly, or facilitate selective uptake via SR-BI (41, 42).
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ies led to stimulation of de novo cholesterol synthesis (68,
69). Likely, the stimulation of SR-B1 and cholesterol syn-
thesis takes place to maintain intracellular cholesterol lev-
els. The occurrence of similar compensatory mechanisms
in the liver might explain the rather faint phenotypic ef-
fects of HL deficiency.
Cholesterol homeostasis is maintained through coordi-
nate regulation of the expression of many genes. If HL
plays a role in cholesterol homeostasis, regulation of HL
expression should fit within the same framework. Busch
and coworkers (70) showed that in HepG2 cells treated
with the HMG-CoA reductase inhibitor mevinolin, the ad-
dition of 25-hydroxycholesterol decreased HMG-CoA re-
ductase expression and increased HL expression. They
suggested that an intermediate of the de novo choles-
terol-synthesizing pathway affects HL expression (71). We
(72) recently found that the activity of HL promoter-
reporter constructs in HepG2 cells is reduced by co-trans-
fection with an SREBP-2 expression vector. SREBP-2 is a
transcription factor that plays a central role in cholesterol
homeostasis (73). A number of observations in humans
support the hypothesis that HL expression is regulated as
an integral part of cholesterol homeostasis. In FH, for ex-
ample, HL activity is relatively high (12, 17). Moriguchi et
al. (12) suggested that this reflects an adaptation to the
low LDLR activity to increase the intracellular cholesterol
pool. Cholesterol synthesis inhibitors that decrease plasma
cholesterol by increasing LDLR activity (by increasing
SREBP-2) may decrease HL expression (28). Hormonal
regulation of HL expression by sex hormones fits in the
same picture. Estrogens stimulate LDLR expression and
decrease HL activity, while androgens have the opposite
effect (74).
Concomitant (opposite) changes in LDLR and HL ac-
tivity may profoundly affect plasma lipoprotein metabo-
lism. As discussed, LDLR, CETP, and HL activity deter-
mine for a large part the efficiency of two different routes
of RCT. Opposite changes in LDLR and HL expression
(e.g., by estrogens/androgens, statins) may result in effi-
cient RCT via either pathway. If both LDLR activity and
HL are decreased (e.g., during hypothyroidism), both
pathways are blocked resulting in a highly increased CAD
risk. In this view, RCT is influenced as a consequence of
(hormonal, dietary) alterations in hepatic cholesterol ho-
meostasis with pro- or anti-atherogenic consequences.
The role of HL in intracellular lipid metabolism may
not be limited to cholesterol homeostasis. By hydrolyzing
HDL phospholipids and triglycerides, and by stimulating
chylomicron-remnant uptake and IDL metabolism, HL
contributes to the uptake of phospholipids and fatty acids
by the liver (Fig. 3). In this way, HL enhances the amount
of lipid components, which may be used for VLDL synthe-
sis. The major precursors for VLDL triglycerides are, how-
ever, fatty acids derived from omental fat stores. Fatty acid
addition to HepG2 cells was found to stimulate HL ex-
pression (72, 75). A similar stimulatory effect of fatty ac-
ids on HL expression in situ would explain the positive
correlation between HL activity and omental fat mass,
and the high HL activity in conditions with a high flux
of fatty acids to the liver (obesity, insulin-resistance,
type 2 diabetes). In this way, HL appears to be coordi-
nately regulated with VLDL triglyceride synthesis. We
found that in HepG2 cells, HL expression is stimulated
by upstream stimulatory factor and inhibited by SREBPs,
transcription factors central in fatty acid metabolism in
the liver (73, 76). This supports such coordinate regula-
tion.
We can only speculate about the physiological meaning
of coordinate regulation. Connelly (5) suggested that HL
is essential for the delivery of certain phospholipids to the
liver. HL, in mediating the uptake of HDL phospholipids,
may thus contribute to the pool of phospholipids in the
liver (Fig. 3).
We hypothesize that in conditions with a high fatty acid
flux to the liver, when hepatic lipids are exported by en-
hanced VLDL secretion, HL is stimulated to maintain in-
tracellular lipid levels (phospholipids, cholesterol) in the
liver.
Obviously, these considerations are highly speculative at
the moment, as quantitative data on the impact of HL on
different metabolic processes are missing. However, these
mechanisms have important consequences if intervention
at the site of HL is considered.
 
Should or can we affect HL activity to lower CAD risk?
 
From these data and considerations, it appears that
there are many uncertainties about the exact role of HL
in lipid metabolism and its impact on atherogenesis. It
seems that the relation of HL with lipid metabolism is very
complex. This limits the feasibility to use HL as a target
for intervention to lower CAD risk. Changes in HL activity
seem to be part of the coordinate regulation of genes in-
volved in lipid metabolism. This predicts that any inter-
vention in HL expression may result in, aside from an ef-
fect on plasma lipoprotein transport, a change in the
expression of other genes and of intracellular lipid ho-
meostasis. Lowering HL activity during hypertriglyceri-
demia may decrease the atherogenic risk due to an im-
proved lipid profile, notably an increased LDL size.
However, the RCT via the “direct” pathway and post-pran-
dial lipid clearing may become impaired unless, at the
same time, LDLR activity is stimulated; vice versa, stimula-
tion of HL expression in FH could result in a further
down-regulation of LDLR activity and increased plasma
LDL levels. The net effect that such changes on athero-
sclerosis is unpredictable.
Another major complication in manipulating HL ex-
pression is that we do not know the exact activity of HL in
vivo. We lack knowledge on the predominance of the in
situ phospholipase or triglyceridase activity and how these
activities vary under different conditions. By non-specifi-
cally altering both activities, unexpected side effects may
occur.
Finally, it should be realized that there are indications
that the atherogenic potential of HL varies with the (ge-
netic) status of other genes (e.g., 
 
CETP
 
). Increasing or de-
creasing HL expression may have varying effects in differ-
ent individuals.
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EPILOGUE
HL is clearly a protein with many faces that affects the
metabolism of many lipoproteins. Either enzymatically or
as a binding protein, it may change the level, the composi-
tion, and metabolism of lipoproteins into a more or less
atherogenic direction. The question of whether HL is a
pro- or anti-atherogenic protein cannot be answered with-
out taking the context in which it is studied into account.
In examining the available data, it appears that high HL
activity is anti-atherogenic in (familial) hypercholesterol-
emia and pro-atherogenic in hypertriglyceridemia. In nor-
molipidemia, HL seems to have little effect on CAD risk.
We hypothesize that, aside from plasma lipoprotein me-
tabolism, HL is an important factor in intracellular lipid
homeostasis of the liver, adrenals, and ovaries. Elucidation
of this role is of great importance.
In view of its apparent involvement in the complex lipid
homeostasis and association with glucose homeostasis, in-
tervention in HL expression may have unexpected effects.
Before intervention in normally regulated HL expression is
considered, the metabolic meaning of changes in HL ex-
pression under different conditions should be known.
 
The authors gratefully acknowledge Dr. R. de Crom for his role
in the design and preparation of the figures.
 
REFERENCES
 
1. Zambon, A., B. G. Brown, S. S. Deeb, and J. D. Brunzell. 2001. He-
patic lipase as a focal point for the development and treatment of
coronary artery disease. 
 
J. Investig. Med.
 
 
 
49:
 
 112–118.
2. Dugi, K. A., K. Brandauer, N. Schmidt, B. Nau, J. G. Schneider, S.
Mentz, T. Keiper, J. R. Schaefer, C. Meissner, H. Kather, M. L. Bah-
ner, W. Fiehn, and J. Kreuzer. 2001. Low hepatic lipase activity is a
novel risk factor for coronary artery disease. 
 
Circulation.
 
 
 
104:
 
 3057–
3062.
3. Perret, B., L. Mabile, L. Martinez, F. Tercé, R. Barbaras, and X.
Collet. 2002. Hepatic lipase: structure/function relationship, syn-
thesis, and regulation. 
 
J. Lipid Res.
 
 
 
43: 
 
1163–1169.
4. Santamarina-Fojo, S., and C. Haudenschild. 2000. Role of hepatic
and lipoprotein lipase in lipoprotein metabolism and atheroscle-
rosis: studies in transgenic and knockout animal models and so-
matic gene transfer. 
 
Int. J. Tissue React.
 
 
 
22:
 
 39–47.
5. Connelly, P. W. 1999. The role of hepatic lipase in lipoprotein me-
tabolism. 
 
Clin. Chim. Acta.
 
 
 
286:
 
 243–255.
6. Cohen, J. C., G. L. Vega, and S. M. Grundy. 1999. Hepatic lipase:
new insights from genetic and metabolic studies. 
 
Curr. Opin. Lipi-
dol.
 
 
 
10:
 
 259–267.
7. Berg, A., I. Frey, M. W. Baumstark, M. Halle, and J. Keul. 1994.
Physical activity and lipoprotein lipid disorders. 
 
Sports Med.
 
 
 
17:
 
6–21.
8. Kong, C., L. Nimmo, T. Elatrozy, V. Anyaoku, C. Hughes, S. Robin-
son, W. Richmond, and R. S. Elkeles. 2001. Smoking is associated
with increased hepatic lipase activity, insulin resistance, dyslipi-
daemia and early atherosclerosis in Type 2 diabetes. 
 
Atherosclerosis.
 
156:
 
 373–378.
9. Baynes, C., A. D. Henderson, V. Anyaoku, W. Richmond, C. L.
Hughes, D. G. Johnston, and R. S. Elkeles. 1991. The role of insu-
lin insensitivity and hepatic lipase in the dyslipidaemia of type 2 di-
abetes. 
 
Diabet. Med.
 
 
 
8:
 
 560–566.
10. Carr, M. C., J. E. Hokanson, A. Zambon, S. S. Deeb, P. H. Barrett,
J. Q. Purnell, and J. D. Brunzell. 2001. The contribution of in-
traabdominal fat to gender differences in hepatic lipase activity
and low/high density lipoprotein heterogeneity. 
 
J. Clin. Endocrinol.
Metab.
 
 
 
86:
 
 2831–2837.
 
11. Allayee, H., K. M. Dominguez, B. E. Aouizerat, R. M. Krauss, J. I.
Rotter, J. Lu, R. M. Cantor, T. W. de Bruin, and A. J. Lusis. 2000.
Contribution of the hepatic lipase gene to the atherogenic lipo-
protein phenotype in familial combined hyperlipidemia. 
 
J. Lipid
Res.
 
 
 
41:
 
 245–252.
12. Moriguchi, E. H., H. Tamachi, and Y. Goto. 1990. Hepatic lipase
activity and high density lipoproteins in familial hypercholesterol-
emia: adaptational mechanisms for LDL-receptor deficient state.
 
Tokai J. Exp. Clin. Med.
 
 
 
15:
 
 401–406.
13. Dugi, K. A., I. M. Feuerstein, S. Hill, J. Shih, S. Santamarina-Fojo,
H. B. Brewer, Jr., and J. M. Hoeg. 1997. Lipoprotein lipase corre-
lates positively and hepatic lipase inversely with calcific atheroscle-
rosis in homozygous familial hypercholesterolemia. 
 
Arterioscler.
Thromb. Vasc. Biol.
 
 
 
17:
 
 354–364.
14. Barth, J. D., H. Jansen, D. Kromhout, J. H. Reiber, J. C. Birken-
hager, and A. C. Arntzenius. 1987. Progression and regression of
human coronary atherosclerosis. The role of lipoproteins, lipases
and thyroid hormones in coronary lesion growth. 
 
Atherosclerosis.
 
68:
 
 51–58.
15. Groot, P. H., W. A. van Stiphout, X. H. Krauss, H. Jansen, A. van
Tol, E. van Ramshorst, S. Chin-On, A. Hofman, S. R. Cresswell, and
L. Havekes. 1991. Postprandial lipoprotein metabolism in normo-
lipidemic men with and without coronary artery disease. 
 
Arterio-
scler. Thromb.
 
 
 
11:
 
 653–662.
16. Zambon, A., S. S. Deeb, A. Bensadoun, K. E. Foster, and J. D. Brun-
zell. 2000. In vivo evidence of a role for hepatic lipase in human
apoB-containing lipoprotein metabolism, independent of its li-
polytic activity. 
 
J. Lipid Res.
 
 
 
41:
 
 2094–2099.
17. Hoogerbrugge, N., and H. Jansen. 1999. Atorvastatin increases
low-density lipoprotein size and enhances high-density lipoprotein
cholesterol concentration in male, but not in female patients with
familial hypercholesterolemia. 
 
Atherosclerosis.
 
 
 
146:
 
 167–174.
18. Jansen, H., A. J. Verhoeven, L. Weeks, J. J. Kastelein, D. J. Halley, A.
van den Ouweland, J. W. Jukema, J. C. Seidell, and J. C. Birken-
hager. 1997. Common C-to-T substitution at position 
 

 
480 of the
hepatic lipase promoter associated with a lowered lipase activity in
coronary artery disease patients. 
 
Arterioscler. Thromb. Vasc. Biol.
 
 
 
17:
 
2837–2842.
19. Zambon, A., J. E. Hokanson, B. G. Brown, and J. D. Brunzell. 1999.
Evidence for a new pathophysiological mechanism for coronary
artery disease regression: hepatic lipase-mediated changes in LDL
density. 
 
Circulation. 99: 1959–1964.
20. Connelly, P. W., and R. A. Hegele. 1998. Hepatic lipase deficiency.
Crit. Rev. Clin. Lab. Sci. 35: 547–572.
21. Guerra, R., J. Wang, S. M. Grundy, and J. C. Cohen. 1997. A he-
patic lipase (LIPC) allele associated with high plasma concentra-
tions of high density lipoprotein cholesterol. Proc. Natl. Acad. Sci.
USA. 94: 4532–4537.
22. Shohet, R. V., G. L. Vega, A. Anwar, J. E. Cigarroa, S. M. Grundy,
and J. C. Cohen. 1999. Hepatic lipase (LIPC) promoter polymor-
phism in men with coronary artery disease. Allele frequency and
effects on hepatic lipase activity and plasma HDL-C concentra-
tions. Arterioscler. Thromb. Vasc. Biol. 19: 1975–1978.
23. Andersen, R. V., H. H. Wittrup, A. Tybjaerg-Hansen, R. Stef-
fensen, P. Schnohr, and B. G. Nordesgaard. 2001. Hepatic lipase
promoter SNPs associated with increased HDL cholesterol and
paradoxically an increased risk of ischemic heart disease: the
copenhagen city heart study. Atherosclerosis. Supplement 2, Ab-
stract W12.1.
24. Fan, Y., R. Laaksonen, T. Janatuinen, R. Vesalainen, P. Nuutila, T.
Koivula, J. Knuuti, and T. Lehtimaki. 2001. Hepatic lipase gene
variation is related to coronary reactivity in healthy young men.
Eur. J. Clin. Invest. 31: 574–580.
25. Hakonson, J. E., S. Cheng, J. K. Snell-Bergeon, B. A. Fijal, M. A.
Grow, C. Hung, H. A. Erlich, J. Erlich, R. H. Eckel, and M. Rewers.
2002. A common promoter polymorphism in the hepatic lipase
gene (LIPC-480CT) is associated with an increase in coronary
calcification in type 1 diabetes. Diabetes. 51: 1208–1213.
26. Hirano, K., S. Yamashita, Y. Kuga, N. Sakai, S. Nozaki, S. Kihara, T.
Arai, K. Yanagi, S. Takami, M. Menju, M. Ishigama, Y. Yoshida, K.
Kameda-Takemura, K. Hayashi, and Y. Matsuzawa. 1995. Athero-
sclerotic disease in marked hyperalphalipoproteinemia. Com-
bined reduction of cholesteryl ester transfer protein and hepatic
triglyceride lipase. Arterioscler. Thromb. Vasc. Biol. 15: 1849–1856.
27. Vega, G. L., L. T. Clark, A. Tang, S. Marcovina, S. M. Grundy, and
J. C. Cohen. 1998. Hepatic lipase activity is lower in African Ameri-
can men than in white American men: effects of 5 flanking poly-
 at M
edical Library Erasm
us M
C on Novem
ber 14, 2006 
w
w
w
.jlr.org
D
ow
nloaded from
 
Jansen, Verhoeven, and Sijbrands Hepatic lipase and atherosclerosis 1361
morphism in the hepatic lipase gene (LIPC). J. Lipid Res. 39: 228–
232.
28. Zambon, A., S. S. Deeb, J. E. Hokanson, B. G. Brown, and J. D.
Brunzell. 1998. Common variants in the promoter of the hepatic
lipase gene are associated with lower levels of hepatic lipase ac-
tivity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler.
Thromb. Vasc. Biol. 18: 1723–1729.
29. Busch, S. J., R. L. Barnhart, G. A. Martin, M. C. Fitzgerald, M. T.
Yates, S. J. Mao, C. E. Thomas, and R. L. Jackson. 1994. Human he-
patic triglyceride lipase expression reduces high density lipopro-
tein and aortic cholesterol in cholesterol-fed transgenic mice. J.
Biol. Chem. 269: 16376–16382.
30. Weng, W., N. A. Brandenburg, S. Zhong, J. Halkias, L. Wu, X. C.
Jiang, A. Tall, and J. L. Breslow. 1999. ApoA-II maintains HDL lev-
els in part by inhibition of hepatic lipase. Studies In apoA-II and
hepatic lipase double knockout mice. J. Lipid Res. 40: 1064–1070.
31. Hedrick, C. C., L. W. Castellani, H. Wong, and A. J. Lusis. 2001. In
vivo interactions of apoA-II, apoA-I, and hepatic lipase contribut-
ing to HDL structure and antiatherogenic functions. J. Lipid Res.
42: 563–570.
32. Mezdour, H., R. Jones, C. Dengremont, G. Castro, and N. Maeda.
1997. Hepatic lipase deficiency increases plasma cholesterol but
reduces susceptibility to atherosclerosis in apolipoprotein E-defi-
cient mice. J. Biol. Chem. 272: 13570–13575.
33. Taylor, J. M. 1997. Transgenic rabbit models for the study of ath-
erosclerosis. Front. Biosci. 2: D298–308.
34. Jansen, H., A. van Tol, J. Auwerx, G. Skretting, and B. Staels. 1992.
Opposite regulation of hepatic lipase and lecithin: cholesterol
acyltransferase by glucocorticoids in rats. Biochim. Biophys. Acta.
1128: 181–185.
35. Cohen, J. C., Z. Wang, S. M. Grundy, M. R. Stoesz, and R. Guerra.
1994. Variation at the hepatic lipase and apolipoprotein AI/CIII/
AIV loci is a major cause of genetically determined variation in
plasma HDL cholesterol levels. J. Clin. Invest. 94: 2377–2384.
36. Hegele, R. A., S. B. Harris, J. H. Brunt, T. K. Young, A. J. Hanley, B.
Zinman, and P. W. Connelly. 1999. Absence of association between
genetic variation in the LIPC gene promoter and plasma lipopro-
teins in three Canadian populations. Atherosclerosis. 146: 153–160.
37. Navab, M., S. Y. Hama, G. P. Hough, C. C. Hedrick, R. Sorenson,
B. N. La Du, J. A. Kobashigawa, G. C. Fonarow, J. A. Berliner, H.
Laks, and A. M. Fogelman. 1998. High density associated enzymes:
their role in vascular biology. Curr. Opin. Lipidol. 9: 449–456.
38. Jansen, H., and W. C. Hulsmann. 1980. Heparin-releasable (liver)
lipase(s) may play a role in the uptake of cholesterol by steroid-
secreting tissues. Trends Biochem. Sci. 5: 265–268.
39. Johnson, W. J., M. J. Bamberger, R. A. Latta, P. E. Rapp, M. C. Phil-
lips, and G. H. Rothblat. 1986. The bidirectional flux of choles-
terol between cells and lipoproteins. Effects of phospholipid de-
pletion of high density lipoprotein. J. Biol. Chem. 261: 5766–5776.
40. Lambert, G., M. J. Amar, P. Martin, J. Fruchart-Najib, B. Foger,
R. D. Shamburek, H. B. Brewer, Jr., and S. Santamarina-Fojo. 2000.
Hepatic lipase deficiency decreases the selective uptake of HDL-
cholesteryl esters in vivo. J. Lipid Res. 41: 667–672.
41. Lambert, G., M. B. Chase, K. Dugi, A. Bensadoun, H. B. Brewer, Jr.,
and S. Santamarina-Fojo. 1999. Hepatic lipase promotes the selec-
tive uptake of high density lipoprotein-cholesteryl esters via the
scavenger receptor B1. J. Lipid Res. 40: 1294–1303.
42. Collet, X., A. R. Tall, H. Serajuddin, K. Guendouzi, L. Royer, H.
Oliveira, R. Barbaras, X. C. Jiang, and O. L. Francone. 1999. Re-
modeling of HDL by CETP in vivo and by CETP and hepatic lipase
in vitro results in enhanced uptake of HDL CE by cells expressing
scavenger receptor B-I. J. Lipid Res. 40: 1185–1193.
43. Ueda, Y., L. Royer, E. Gong, J. Zhang, P. N. Cooper, O. Francone,
and E. M. Rubin. 1999. Lower plasma levels and accelerated clear-
ance of high density lipoprotein (HDL) and non-HDL cholesterol
in scavenger receptor class B type I transgenic mice. J. Biol. Chem.
274: 7165–7171.
44. Fielding, C. J., and P. E. Fielding. 2001. Cellular cholesterol efflux.
Biochim. Biophys. Acta. 1533: 175–189.
45. von Eckardstein, A., J. R. Nofer, and G. Assmann. 2000. Acceleration
of reverse cholesterol transport. Curr. Opin. Cardiol. 15: 348–354.
46. von Eckardstein, A., J. R. Nofer, and G. Assmann. 2001. High density
lipoproteins and arteriosclerosis. Role of cholesterol efflux and re-
verse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21: 13–27.
47. Hill, S. A., and M. J. McQueen. 1997. Reverse cholesterol trans-
port–a review of the process and its clinical implications. Clin. Bio-
chem. 30: 517–525.
48. Nofer, J. R., B. Kehrel, M. Fobker, B. Levkau, G. Assmann, and A.
Eckardstein. 2002. HDL and arteriosclerosis: beyond reverse cho-
lesterol transport. Atherosclerosis. 161: 1–16.
49. Ginsberg, H. N. 1996. Diabetic dyslipidemia: basic mechanisms
underlying the common hypertriglyceridemia and low HDL cho-
lesterol levels. Diabetes. 45(Suppl. 3): S27–30.
50. Demant, T., L. A. Carlson, L. Holmquist, F. Karpe, P. Nilsson-Ehle,
C. J. Packard, and J. Shepherd. 1988. Lipoprotein metabolism in
hepatic lipase deficiency: studies on the turnover of apolipopro-
tein B and on the effect of hepatic lipase on high density lipopro-
tein. J. Lipid Res. 29: 1603–1611.
51. Jansen, H., G. Chu, C. Ehnholm, J. Dallongeville, V. Nicaud, and
P. J. Talmud. 1999. The T allele of the hepatic lipase promoter
variant C-480T is associated with increased fasting lipids and HDL
and increased preprandial and postprandial LpCIII:B: European
Atherosclerosis Research Study (EARS) II. Arterioscler. Thromb. Vasc.
Biol. 19: 303–308.
52. Asami, T., T. Ciomartan, and M. Uchiyama. 1999. Thyroxine in-
versely regulates serum intermediate density lipoprotein levels in
children with congenital hypothyroidism. Pediatr. Int. 41: 266–269.
53. Krauss, R. M. 1987. Relationship of intermediate and low-density
lipoprotein subspecies to risk of coronary artery disease. Am. Heart
J. 113: 578–582.
54. Havel, R. J. 2000. Genetic underpinnings of LDL size and density:
a role for hepatic lipase? Am. J. Clin. Nutr. 71: 1390–1391.
55. Austin, M. A., P. J. Talmud, L. A. Luong, L. Haddad, I. N. Day, B.
Newman, K. L. Edwards, R. M. Krauss, and S. E. Humphries. 1998.
Candidate-gene studies of the atherogenic lipoprotein phenotype:
a sib-pair linkage analysis of DZ women twins. Am. J. Hum. Genet.
62: 406–419.
56. Austin, M. A., K. Stephens, C. E. Walden, and E. Wijsman. 1999.
Linkage analysis of candidate genes and the small, dense low-den-
sity lipoprotein phenotype. Atherosclerosis. 142: 79–87.
57. Jansen, H., W. Hop, A. van Tol, A. V. Bruschke, and J. C. Birken-
hager. 1994. Hepatic lipase and lipoprotein lipase are not major
determinants of the low density lipoprotein subclass pattern in
human subjects with coronary heart disease. Atherosclerosis. 107:
45–54.
58. Yu, K. C., and A. D. Cooper. 2001. Postprandial lipoproteins and
atherosclerosis. Front. Biosci. 6: D332–354.
59. Fan, J., J. Wang, A. Bensadoun, S. J. Lauer, Q. Dang, R. W. Mahley,
and J. M. Taylor. 1994. Overexpression of hepatic lipase in trans-
genic rabbits leads to a marked reduction of plasma high density
lipoproteins and intermediate density lipoproteins. Proc. Natl.
Acad. Sci. USA. 91: 8724–8728.
60. Pihlajamaki, J., L. Karjalainen, P. Karhapaa, I. Vauhkonen, M. R.
Taskinen, S. S. Deeb, and M. Laakso. 2000. G-250A substitution in
promoter of hepatic lipase gene is associated with dyslipidemia
and insulin resistance in healthy control subjects and in members
of families with familial combined hyperlipidemia. Arterioscler.
Thromb. Vasc. Biol. 20: 1789–1795.
61. Jansen, H., D. M. Waterworth, V. Nicaud, C. Ehnholm, and P. J.
Talmud. 2001. Interaction of the common apolipoprotein C–III
(APOC3-482C  T) and hepatic lipase (LIPC-514C  T) pro-
moter variants affects glucose tolerance in young adults. European
Atherosclerosis Research Study II (EARS-II). Ann. Hum. Genet. 65:
237–243.
62. Baynes, C., A. D. Henderson, V. Anyaoku, W. Richmond, D. G.
Johnston, and R. S. Elkeles. 1991. The influence of regional adi-
posity on atherogenic risk factors in men and women with type 2
diabetes. Diabet. Med. 8: 458–463.
63. Purnell, J. Q., S. E. Kahn, J. J. Albers, D. N. Nevin, J. D. Brunzell,
and R. S. Schwartz. 2000. Effect of weight loss with reduction of in-
tra-abdominal fat on lipid metabolism in older men. J. Clin. Endo-
crinol. Metab. 85: 977–982.
64. Huuskonen, J., and C. Ehnholm. 2000. Phospholipid transfer pro-
tein in lipid metabolism. Curr. Opin. Lipidol. 11: 285–289.
65. van Tol, A. 2002. Phospholipid transfer protein. Curr. Opin. Lipidol.
13: 135–139.
66. Vieira-van Bruggen, D., I. Kalkman, T. van Gent, A. van Tol, and
H. Jansen. 1998. Induction of adrenal scavenger receptor BI
and increased high density lipoprotein-cholesteryl ether uptake
by in vivo inhibition of hepatic lipase. J. Biol. Chem. 273: 32038–
32041.
67. Wang, N., W. Weng, J. L. Breslow, and A. R. Tall. 1996. Scavenger
receptor BI (SR-BI) is up-regulated in adrenal gland in apolipo-
protein A-I and hepatic lipase knock-out mice as a response to de-
 at M
edical Library Erasm
us M
C on Novem
ber 14, 2006 
w
w
w
.jlr.org
D
ow
nloaded from
 
1362 Journal of Lipid Research Volume 43, 2002
pletion of cholesterol stores. In vivo evidence that SR-BI is a func-
tional high density lipoprotein receptor under feedback control. J.
Biol. Chem. 271: 21001–21004.
68. Jansen, H., and W. J. de Greef. 1988. L-type lipase activity in ova-
ries of superovulated rats. Relation to cholesterol homeostasis.
Mol. Cell. Endocrinol. 57: 7–15.
69. Jansen, H. 1985. Inhibition of liver lipase in vivo leads to induction
of de novo cholesterol synthesis in rat liver. Biochem. Biophys. Res.
Commun. 131: 574–578.
70. Busch, S. J., R. L. Barnhart, G. A. Martin, M. A. Flanagan, and R. L.
Jackson. 1990. Differential regulation of hepatic triglyceride lipase
and 3-hydroxy-3-methylglutaryl-CoA reductase gene expression in a
human hepatoma cell line, HepG2. J. Biol. Chem. 265: 22474–22479.
71. Busch, S. J., G. A. Martin, R. L. Barnhart, M. A. Flanagan, and R. L.
Jackson. 1991. Regulation of hepatic lipase expression by an inter-
mediate of the cellular cholesterol biosynthetic pathway. Adv. Exp.
Med. Biol. 285: 65–69.
72. Botma, G. J., A. J. Verhoeven, and H. Jansen. 2001. Molecular basis
of the association between hepatic lipase activity and obesity, hy-
pertriglyceridemia and insulin resistance. Circulation. American
Heart Association meeting, Anaheim, California. 2001
73. Goldstein, J. L., R. B. Rawson, and M. S. Brown. 2002. Mutant
mammalian cells as tools to delineate the sterol regulatory ele-
ment-binding protein pathway for feedback regulation of lipid syn-
thesis. Arch. Biochem. Biophys. 397: 139–148.
74. Croston, G. E., L. B. Milan, K. B. Marschke, M. Reichman, and
M. R. Briggs. 1997. Androgen receptor-mediated antagonism of es-
trogen-dependent low density lipoprotein receptor transcription
in cultured hepatocytes. Endocrinology. 138: 3779–3786.
75. Nimmo, L., A. J. McColl, J. Z. Rosankiewicz, W. Richmond, and
R. S. Elkeles. 1997. Regulation of hepatic lipase expression in
HepG2 cells. Biochem. Soc. Trans. 25: S689.
76. Sul, H. S., M. J. Latasa, Y. Moon, and K. H. Kim. 2000. Regulation of
the fatty acid synthase promoter by insulin. J. Nutr. 130: 315S–320S.
 at M
edical Library Erasm
us M
C on Novem
ber 14, 2006 
w
w
w
.jlr.org
D
ow
nloaded from
 
